Linked Data API

Show Search Form

Search Results

77265
star this property registered interest false more like this
star this property date less than 2014-07-10more like thismore than 2014-07-10
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Lyme Disease more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether, in December 2011, the Clinical Pathology Accreditation Service was made aware of modifications by the Health Protection Agency’s Lyme Borreliosis Unit to the Trinity Biotech immunoblot kit to be used for testing human cerebrospinal fluid. more like this
star this property tabling member printed
The Countess of Mar more like this
star this property uin HL999 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-07-24more like thismore than 2014-07-24
star this property answer text <p>The former Health Protection Agency's Lyme Borreliosis Unit (HPA LBU) was accredited by Clinical Pathology Accreditation who had access to, and was able to review, all the standard operating procedures of the unit.</p><p> </p><p>The Trinity Biotech Lyme Western Blot is a qualitative in vitro assay for the detection of Immunoglobulin (IgG or IgM) antibodies in human samples against specific antigens/proteins of <em>Borrelia afzelii, Borrelia garinii and Borrelia burgdorferi</em>. The Trinity Biotech Lyme Western Blot is intended as a confirmatory assay for use in testing human samples which have been previously found to be positive or equivocal using an Enzyme Immunoassay and Immunofluroescent Assay or other appropriate screening method. Positive second-tier results are supportive evidence of infection with <em>B. burgdorferi</em>. The diagnosis of Lyme disease should be made based on history and symptoms (such as erythema migrans), and other laboratory data, in addition to the presence of antibodies to <em>B. burgdorferi</em>. The Trinity Biotech blot has been in use since 2007 by the former HPA’s LBU for testing cerebrospinal fluid (CSF) and proved very reliable. This technique has also been in use widely across Europe during this period as a diagnostic test using CSF as a sample to support the diagnosis of neuroborreliosis.</p>
star this property answering member printed Earl Howe more like this
star this property question first answered
less than 2014-07-24T12:32:59.6647091Zmore like thismore than 2014-07-24T12:32:59.6647091Z
star this property answering member
2000
star this property label Biography information for Earl Howe more like this
star this property tabling member
1861
unstar this property label Biography information for The Countess of Mar more like this
77264
star this property registered interest false more like this
star this property date less than 2014-07-10more like thismore than 2014-07-10
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Lyme Disease more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government when the testing of the cerebrospinal fluid of patients suspected of having Lyme disease using the Trinity Biotech kit at the Health Protection Agency’s Lyme Borreliosis Unit began; how many patients' samples were tested in that way; and how many patients were recorded as being positive over that period of time. more like this
star this property tabling member printed
The Countess of Mar more like this
star this property uin HL998 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-07-24more like thismore than 2014-07-24
star this property answer text <p>The Trinity Biotech blot has been in use since 2007 by the former Health Protection Agency's Lyme Borreliosis Unit for testing cerebrospinal fluid (CSF) and proved very reliable. It has also been used in this way by other laboratories in Europe. However, CSF antibodies will not be present if there is no evidence of any other antibodies in the serum. Data is not collected centrally on specific samples from patients as the final diagnosis is made by the clinician on the basis of the test results and the clinical presentation.</p> more like this
star this property answering member printed Earl Howe more like this
star this property question first answered
less than 2014-07-24T12:31:17.2846277Zmore like thismore than 2014-07-24T12:31:17.2846277Z
star this property answering member
2000
star this property label Biography information for Earl Howe more like this
star this property tabling member
1861
unstar this property label Biography information for The Countess of Mar more like this
386888
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government which of the four phase 2 or 3 clinical trials for systemic amyloidosis approved since 2004 are still ongoing; and whether any of the trials have produced sufficient positive outcomes to encourage commercial development. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL997 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
star this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL995 more like this
HL996 more like this
star this property question first answered
less than 2015-07-14T15:34:29.553Zmore like thismore than 2015-07-14T15:34:29.553Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
star this property title 2013-14 Annual Report more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386887
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether there are currently any trials for systemic amyloidosis in humans being conducted by the National Institute of Health Research charities or the commercial sector. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL996 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
star this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL995 more like this
HL997 more like this
star this property question first answered
less than 2015-07-14T15:34:29.297Zmore like thismore than 2015-07-14T15:34:29.297Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
star this property title 2013-14 Annual Report more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386886
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Bone Marrow Disorders more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether they will place in the Library of the House any publications resulting from the phase 3 clinical trials approved for the potential treatment of systemic amyloidosis or multiple myeloma; and what is the National Institute of Health Research’s assessment of progress in these areas. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL995 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
star this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL996 more like this
HL997 more like this
star this property question first answered
less than 2015-07-14T15:34:29.197Zmore like thismore than 2015-07-14T15:34:29.197Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
star this property title 2013-14 Annual Report more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386885
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Myeloma more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government when they expect the National Institute of Health Research Technology Assessment programme to publish initial findings from its assessment of the benefits of antibiotic prophylaxis and its effect on healthcare associated infections in myeloma patients. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL994 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-09more like thismore than 2015-07-09
star this property answer text <p>This trial is led by the University of Birmingham. The project is recruiting ahead of schedule and expects to reach its target of 800 in the near future. The target was to do so by the end of November 2015. Publication of initial findings is expected in 2017.</p><p> </p> more like this
star this property answering member printed Lord Prior of Brampton more like this
star this property question first answered
less than 2015-07-09T13:00:57.7Zmore like thismore than 2015-07-09T13:00:57.7Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386884
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what progress has been made on setting up a study to image amyloid deposition in systemic amyloidosis using hybrid positron emission tomography-magnetic resonance imaging; where the study is located; how many patients have been recruited; when the study is expected to complete its initial work; and where the results will be published. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL993 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
star this property answer text <p>This is a single centre study at University College London Hospital. It has now been set up and one patient has been recruited and scanned. The current planned date for end of recruitment is 1 October 2016. It is anticipated that the data will be analysed and submitted for publication in a peer reviewed journal within a year of the end of recruitment.</p><p> </p> more like this
star this property answering member printed Lord Prior of Brampton more like this
star this property question first answered
less than 2015-07-14T15:36:20.96Zmore like thismore than 2015-07-14T15:36:20.96Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
58574
star this property registered interest false more like this
star this property date less than 2014-06-05more like thismore than 2014-06-05
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Mental Health Services more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether personality disorder services remain a priority commitment for the National Health Service; and if so, what guidance is provided to NHS England to ensure that quality services continue to be commissioned. more like this
star this property tabling member printed
Lord Alderdice more like this
star this property uin HL99 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-06-19more like thismore than 2014-06-19
star this property answer text Personality disorder services remain a priority commitment for the National Health Service. In 2011 the Government published No health, without mental health, a cross Government mental health outcomes strategy for people of all ages which remains the Government's vision for improving services for people with mental health problems; this specifically includes people with personality disorders. The Mandate to NHS England makes clear that by March 2015, we expect NHS England to make measurable progress towards achieving true parity of esteem between mental and physical health and that everyone who needs it should have timely access to evidence-based services. more like this
star this property answering member printed Earl Howe more like this
star this property question first answered
less than 2014-06-19T11:56:04.2951219Zmore like thismore than 2014-06-19T11:56:04.2951219Z
star this property answering member
2000
star this property label Biography information for Earl Howe more like this
star this property tabling member
3478
unstar this property label Biography information for Lord Alderdice more like this
947606
star this property registered interest false more like this
star this property date less than 2018-07-24more like thismore than 2018-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading General Practitioners: Insurance more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the difference in the insurance premium paid by GPs in England and Scotland; and what assessment they have made of the reasons for such difference. more like this
star this property tabling member printed
Lord Mawson more like this
star this property uin HL9874 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-07-26more like thismore than 2018-07-26
star this property answer text <p>General practitioners (GPs) are required to have adequate and appropriate indemnity or insurance arrangements to cover clinical negligence liabilities.</p><p>We do not have data showing the difference on insurance premiums, which are a very small proportion of the market in England. The Department is aware that there is a difference in the cost of clinical negligence indemnity subscriptions paid by GPs in England and Scotland. No assessment has been made for the reasons for such difference.</p><p>Health is a devolved matter and it is for the devolved administrations to make their own decisions about health policies in their own territories.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-07-26T12:45:16.4Zmore like thismore than 2018-07-26T12:45:16.4Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
3830
unstar this property label Biography information for Lord Mawson more like this
947567
star this property registered interest false more like this
star this property date less than 2018-07-24more like thismore than 2018-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 remove filter
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading PrescQIPP more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assurances they have received from PresQIPP that when providing guidance to Clinical Commissioning Groups on commissioning decisions it has taken the views of patient stakeholders into account. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL9849 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-07-26more like thismore than 2018-07-26
star this property answer text <p>We have not made any assessment on the accuracy and advice provided by PrescQIPP. Nor have we made any assessment on whether the advice provided by PrescQIPP to clinical commissioning groups (CCGs) is consistent with national guidelines on the prescription of liothyronine to National Health Service patients. We can confirm that we have not received any assurances from PrescQIPP on whether or not it has taken patient stakeholder views into account as it is the responsibility of CCGs to seek any such assurances.</p><p>PrescQIPP is an independent social enterprise and it is for CCGs to decide whether and how they take that guidance into account when making decisions. However, NHS England expects CCGs to have due regard to the guidance <em>Items which should not routinely be prescribed in primary care: Guidance for CCGs,</em> published in November 2017 by NHS England and NHS Clinical Commissioners when considering the prescribing of liothyronine. A copy of the guidance is attached.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL9847 more like this
HL9848 more like this
star this property question first answered
less than 2018-07-26T12:46:36.573Zmore like thismore than 2018-07-26T12:46:36.573Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
star this property file name items-which-should-not-be-routinely-precscribed-in-pc-ccg-guidance.pdf more like this
star this property title Items which should not routinely be prescribed more like this
star this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this